A portfolio of ten thousand patents is worth nothing in a negotiation until you know which ones read on the product across the table. The count on the slide impresses no one on the other side. What moves a licensing conversation, an enforcement decision, or a cross license is a specific claim mapped to a specific feature in a specific product, with a reason it reads the way you say it does.

The amount that sits unmapped is hard to ignore. Depending on the study, between 90 and 95 percent of patents are never licensed or commercialized, and by one analysis only about 2.9 percent of US corporate patents are ever licensed even once (ScienceDirect, IPWatchdog). Some of that is defensive filing and some is deliberate blocking. A large share is simpler: nobody had time to work out which assets actually read on what the market sells, so the portfolio kept growing and the mapping never got done.

The mapping is the hard part, for real reasons. Doing it by hand means reading a target product, reading your claims, and forming a defensible view on whether one covers the other, then repeating that across hundreds or thousands of assets. It is slow, expensive, and the first thing to slip when the docket is full. So the question that actually pays, which of our patents create a position against this company's product, is the one that most often goes unanswered.

ArcPrime's infringement-likelihood asset matching answers it. You point it at a target product, and it surfaces the assets most likely to read on that product, each scored with a percentage and a written rationale you can inspect. The reasoning names the product, the feature, and why a claim may reach it. You judge the call. It draws on both the documents you upload and public sources, so the analysis reflects what you know internally and what is visible in the market.

The score is deliberately conservative, and that is a feature. ArcPrime recently tightened the model behind these figures, so the likelihood percentages it reports came down. A careful number that holds up is worth far more than an optimistic one that does not.

A likelihood score is a prioritization tool, not a legal opinion, and ArcPrime treats it that way. It tells you where to look first and gives you the reasoning to start from, so your attorneys spend judgment on the ten assets that matter for a licensing or enforcement decision instead of the ten thousand that might. The infringement read, the claim construction, the decision to send a letter, those stay with your team.

Most in house teams sit on more potential position than they can see, because surfacing it has always meant work nobody had time for. ArcPrime is built to do that work for you, so the value already sitting in your portfolio becomes something you can act on. To find out which of your assets read on a product you care about, book a conversation.